Ownership and insider activity for Inovio Pharmaceuticals, Inc. (INO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen.
Price
| Price | $1.15 |
| Market Cap | $79M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-20 | YARNO WENDY L | A-Award | 41,800 | $51K |
| 2026-05-20 | YARNO WENDY L | A-Award | 34,200 | |
| 2026-05-20 | Shepard Jay | A-Award | 41,800 | $51K |
| 2026-05-20 | Shepard Jay | A-Award | 34,200 | |
| 2026-05-20 | Miller Ann Calby | A-Award | 41,800 | $51K |
| 2026-05-20 | Miller Ann Calby | A-Award | 34,200 | |
| 2026-05-20 | Weiner David B. | A-Award | 41,800 | $51K |
| 2026-05-20 | Weiner David B. | A-Award | 34,200 | |
| 2026-05-20 | Zoth Lota S. | A-Award | 41,800 | $51K |
| 2026-05-20 | Zoth Lota S. | A-Award | 34,200 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.1M | $23.8M | $23.7M | $22.2M | $250.7M | $71.1M | $46.3M | $14.3M | $65.8M | $44.3M |
| Short-term Investments | $85.6M | $103.6M | $57.5M | $67.3M | $160.9M | $330.2M | $206.7M | $131.0M | $28.3M | $14.2M |
| Receivables | $16.6M | $6.5M | $4.1M | $2.0M | $19.1M | $8.0M | $11.7M | $2.4M | $1.2M | $450 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $124.6M | $138.4M | $87.8M | $94.2M | $471.2M | $448.4M | $315.2M | $153.1M | $97.8M | $61.1M |
| Property, Plant & Equipment | $9.0M | $18.3M | $15.9M | $26.6M | $24.1M | $29.0M | $18.0M | $14.5M | $11.8M | $9.1M |
| Goodwill | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | 0 | 0 | 0 |
| Intangible Assets | $7.6M | $6.0M | $4.8M | $3.7M | $3.1M | $2.6M | $2.1M | 0 | 0 | 0 |
| Total Assets | $173.7M | $187.2M | $131.1M | $144.0M | $539.8M | $495.9M | $348.5M | $171.0M | $113.2M | $74.3M |
| Accounts Payable | $7.0M | $8.5M | $11.0M | $7.6M | $1.5M | $28.0M | $21.1M | $4.6M | $6.4M | $2.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $16.8M | 0 | 0 |
| Total Current Liabilities | $43.8M | $35.4M | $35.3M | $32.0M | $41.7M | $65.7M | $96.9M | $42.6M | $35.3M | $43.7M |
| Long-term Debt | 0 | 0 | 0 | $77.0M | $18.7M | $15.0M | $16.6M | 0 | 0 | 0 |
| Total Liabilities | $50.3M | $44.8M | $44.1M | $138.5M | $78.6M | $96.3M | $126.2M | $53.6M | $44.7M | $50.2M |
| Retained Earnings | -$434.8M | -$523.4M | -$620.4M | -$739.8M | -$906.2M | -$1.21B | -$1.49B | -$1.62B | -$1.73B | -$1.82B |
| Total Equity | $123.3M | $142.4M | $86.9M | $3.4M | $461.1M | $399.7M | $222.4M | $117.3M | $68.5M | $24.1M |
| Total Debt | 0 | 0 | 0 | $99.5M | $39.0M | $33.0M | $32.1M | $30.2M | $11.9M | $9.4M |
| Net Debt | -$104.8M | -$127.4M | -$81.2M | $10.0M | -$372.6M | -$368.3M | -$220.9M | -$115.1M | -$82.2M | -$49.1M |
| Working Capital | $80.8M | $103.0M | $52.5M | $62.2M | $429.5M | $382.7M | $218.4M | $110.5M | $62.5M | $17.5M |
Financial Health
| Debt / Equity | 0.39 |
| Current Ratio | 1.40 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -36.80 |
Profitability
| Return on Equity | -352.53% |
| Return on Invested Capital | -259.45% |
| Return on Assets | -114.31% |
| Gross Margin | 100.00% |
| Operating Margin | -132871.32% |
| Net Margin | -130000.00% |
Related companies: ABOS · ACTU · AGEN · ALEC · FATE · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of INO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks